Neuromodulation Therapy for Schizophrenia
(TMSNS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn if an accelerated form of neuromodulation therapy can help improve negative symptoms of schizophrenia. Negative symptoms can include low motivation, reduced emotional expression, and difficulty with social interaction. The study will also look at how safe and tolerable this treatment is when given over a short period of time.
Participants will be randomly assigned to receive either active neuromodulation therapy or sham (placebo) stimulation. The study will also compare two different ways of choosing where to place the stimulation.
We want to learn whether this accelerated treatment approach is safe and feasible for people with schizophrenia, whether negative symptoms improve after treatment, and whether the way the stimulation site is chosen affects outcomes
Participants will be asked to complete clinical interviews and questionnaires, undergo a brain scan, receive neuromodulation therapy or sham stimulation over five consecutive days, and attend follow-up visits after treatment
This study is being conducted at three hospitals in Canada and is designed to help plan larger studies in the future.
Who Is on the Research Team?
David Benrimoh, MD.CM., MSc., MSc., FRCPC
Principal Investigator
McGill University, Department of Psychiatry
Stéphane Potvin, PhD
Principal Investigator
Institut Universitaire en Santé Mentale de Montréal
Lena Palaniyappan, MD, PhD
Principal Investigator
Douglas Mental Health Institute
Olivier Roy, MD
Principal Investigator
Centre de recherche CERVO - Université Laval
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive accelerated neuromodulation therapy or sham stimulation over five consecutive days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Accelerated Neuromodulation Therapy
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Participants receive iTBS over five consecutive days (ten sessions/day) targeting the left dorsolateral prefrontal cortex using neuronavigation-guided targeting.
Participants receive iTBS over five consecutive days (ten sessions/day) targeting the left dorsolateral prefrontal cortex using BEAM-F3 targeting.
Participants receive sham iTBS over five consecutive days (ten sessions/day) using the same session structure and procedures as active treatment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Douglas Mental Health University Institute
Lead Sponsor
Centre de recherche CERVO
Collaborator
Magnus Medical
Industry Sponsor
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.